24/7 BIOPHARMA - issue 1 / October 2024

RENAISSANCE LAKEWOOD

What are the possibilities of nasal drug delivery?

Offering non-invasive delivery and ease-of use, a fast onset of action and improvements in bioavailability, nasal administration is experiencing increased demand across many different indications. The nasal drug delivery market was worth US$19 billion in 2022, and is still seeing continued growth, expecting to reach US$30 billion by 2030 1 . Nasal administration is a promising delivery route for both formulations containing new chemical entities (NCEs) and also the repositioning of already approved therapies through the 505(b)(2) regulatory pathway. While nasal administration offers the opportunity to deliver innovative products, there are still major challenges in the research and development (R&D) and clinical manufacturing of nasal products. The pharmaceutical industry must tackle these obstacles to lay the groundwork for effective product scaling and commercialization, ultimately realizing the full potential of nasal drug delivery. In this article, Eric Kaneps, Vice-President of Sales & Marketing at Renaissance Lakewood, LLC will explore the advantages of nasal drug delivery compared to other administration routes, as well as the challenges associated with R&D and clinical manufacturing.

The emergence of more research studies and clinical data has increased the understanding of nasal drug delivery, opening it up to different types of drug products 2 . This has taken it from an administration route predominantly used in local treatments for rhinitis and decongestion to a delivery method explored across many different applications. Intranasal delivery is now being explored in Parkinson’s rigidity, migraine, panic attacks, Alzheimer’s disease, multiple sclerosis attacks and cardiovascular events 3 . The advantages of nasal drug delivery compared to other administration routes include: Nasal administration offers a rapid onset of action for both local and systemic delivery. Acting locally, drugs can be delivered directly to the brain from the nasal cavity. As it is highly vascularized and rich in immune cell populations, the nasal mucosa can also help with rapid delivery and high systemic availability 4 . Nasal drug delivery avoids first-pass metabolism as it bypasses the liver, which allows drug products to be - Rapid delivery, both locally and systemically

56

TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024